Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SRI International has received two preclinical services contracts of $17.4m from the National Heart, Lung, and Blood Institute (NHLBI).
Subscribe to our email newsletter
SRI researchers will support NHLBI’s Science Moving TowArds Research Translation and Therapy (SMARTT) Program to provide resources that assist translation to the clinic of novel therapeutics for the treatment of heart, lung, and blood diseases.
SRI was awarded an $11.5m contract to lead a Pharmacology and Toxicology Center that will work cooperatively with NHLBI and other organizations to provide rapid and cost-effective studies for potential therapies.
SRI has also received $5.9m contract to provide a Non-Biologics and Small Molecules Production Facility for the SMARTT Program.
The overall objective of the contract is to support translational research and provide services as an FDA-defined current good manufacturing practice (cGMP) facility.
Researchers will conduct pharmacology and preclinical studies with candidate drugs and develop scientific data such as treatment regimens and efficacy studies needed to support US Food and Drug Administration (FDA) applications for new medications.
SRI preclinical safety director Hanna Ng said their qualified and experienced team is pleased to support this important translational research program that will lead the way towards human clinical safety and efficacy studies with the best candidate drugs.